The United State anchors North American demand for ATLL treatment, and North America was the largest region in this market in 2025. The patient pool is small, but demand is shaped by the disease’s aggressive course and poor prognosis in the acute and lymphoma subtypes, plus a rising HTLV-1 burden in endemic regions such as the Caribbean. Chemotherapy still made up about 65% of the global...